Biogen is cutting 2022 expenses for Q2, profit forecast is raised
July 20, 2022 at 15:57 PM EDT
Biogen's second quarter expectations were soundly exceeded. Biogen was able to do this by slashing spending on the controversial drug Aduhelm.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|